Accuracy and User Performance Evaluation of PixoTest HbA1c Measurement System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-01

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the accuracy user performance of PixoTest HbAc1 measurement system and to collect feedback from subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HbA1c Prediction Model in Patients With Type 2 Diabetes

NCT05824286

Diabetes Mellitus, Type 2

UNKNOWN NA

Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?

NCT02439684

Diabetes Mellitus

COMPLETED

Prediction to Detect Pre-DM/DM in a Chinese Population

NCT05116319

Diabetes Mellitus

COMPLETED

Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes

NCT03519529

Type2 Diabetes

COMPLETED

Evaluation of Innovated Screening Tools for Type 2 Diabetes Among Chinese Population(SENSIBLE STUDY I)

NCT03025919

Type II Diabetes Mellitus

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to WHO report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. In 2012 alone diabetes caused 1.5 million death. Tight glucose control is essential for prevention of complications in people with diabetes. The Diabetes Control and Complications Trial (DCCT) provided direct evidence the relationship between HbA1c level and risks for diabetic complications in diabetes. Based on the results of the DCCT, the American Diabetes Association (ADA) has published recommendations for HbA1c and plasma glucose levels that are widely used. HbA1c testing can be performed at any time of day and without special patient preparation, it is more convenient for patients and even measuring fasting plasma glucose.

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range. .Most diabetes patients will go to hospital to measurement HbA1c, but should wait few days for test result. Most diabetes patient maybe not measurement HbA1c so many time per year. The PixoTest HbA1c measurement system can give result for a few minutes at home. The diabetes patient can measure HbA1c at home don't need go to hospital.

The PixoTest HbA1c measurement system is defined as the respective reagent system and the corresponding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.

This study is designed to test the accuracy and user performance of the Pixotest HbA1c measurement system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes HbA1c

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Each subject should draw two tubes of venous blood in the K2-EDTA. One tube should be tested by POC operator as a study participant using the PixoTest POCT System. The other tube takes 1c.c. blood sample from K2-EDTA to analyzed with a comparison method.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 diabetic patients

1. 20 years or older.
2. Willing to participate in the study, able to read and provide written informed consent form.
3. HCT 25\~65%.
4. Subjects including healthy subjects, outpatients, and inpatients.

Group Type EXPERIMENTAL

in-vitro

Intervention Type DIAGNOSTIC_TEST

responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

in-vitro

responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years or older.
2. Willing to participate in the study, able to read and provide written informed consent form.
3. HCT 25\~65%.
4. Subjects including healthy subjects, outpatients and inpatients.

2. Hemophilia or any other bleeding disorder
3. Reports having an infection with a blood borne pathogen (e.g. HIV, hepatitis)

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No